概括
像CPS1和BMPR2这样的基因中的遗传变异与新生儿持续性肺高血压 (PPHN) 有关. 然而,对婴儿这些遗传联系的研究是有限的,并产生不一致的结果.
科学领域:
- 新生儿医学 新生儿医学
- 遗传学 遗传学 是一个
- 儿童心脏病学 儿童心脏病学
背景情况:
- 新生儿持续性肺高血压 (PPHN) 影响1.9/1000个活产婴儿.
- PPHN是由出生后循环过渡障碍引起的.
- 在PPHN中,死亡率很高 (4-33%).
研究的目的:
- 系统地审查与PPHN相关的遗传变异.
- 专注于没有遗传综合征的满期和晚期早产婴儿.
- 确定导致PPHN的遗传因素.
主要方法:
- 在 MEDLINE,SCOPUS 和 COCHRANE 数据库中进行了搜索.
- 包括队列研究,病例控制研究和病例系列.
- 分析了9项涉及1494名参与者的研究.
主要成果:
- 在CPS1,CRHR1,NOTCH3,EDN1,EPAS1,WWC2,ABCA3,RFX3,EP300,GNA11,PKLR,SLC2A1,BMPR2和EGLN1中发现了PPHN与变体之间的关联.
- 其中91%的研究质量中等到良好.
- 一项研究发现,与ACE基因变异无关.
结论:
- 对PPHN常见遗传变异的研究是有限的.
- 现有的研究使用小队列和候选基因方法.
- 结果在各个研究中不一致,突出了进一步研究的必要性.
相关概念视频
Incomplete Dominance
Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


